This site will look much better in a browser that supports web standards, but it is accessible to any browser or Internet device.

Skip Navigation skip menu and banner
University of Wyoming

UW Technologies Available for Licensing

 

LICENSED - Technology Disclosures: 05-094 Treatments for Cardiovascular Disease - LICENSED
 

Cardiovascular disease is the leading cause of mortality and morbidity in the advanced world. Diabetes affects over 15 million people in the United States and diabetes-related cardiovascular disease helps make it the seventh leading cause of death in the US. Researchers at the University of Wyoming School of Pharmacy have discovered and developed an innovative class of compounds that may be important in the treatment and control cardiovascular disease. This patent-pending treatment is described below:

05-094 - Application of Chromium Complexes in the Treatment of Diabetes, Obesity, and Related Diseases

Insulin resistance, concomitant with type II diabetes and obesity, is a major risk factor for cardiovascular disease. Chromium complexes, such as chromium picolinate, are often used as dietary supplements to improve insulin sensitivity. However, toxicity associated with the currently marketed chromium picolinate ligand has compromised its therapeutic value. Researchers at the University of Wyoming have synthesized a new, novel chromium complex which can be used in the treatment of diabetes, insulin resistance, and obesity, and most importantly with significant advantages over existing chromium drugs.

First, the new chromium complex does not cause DNA damage like the currently marketed chromium complexes (chromium picolinate). The new complex therefore avoids the toxicity and compromised therapeutic value. Second, the new complex is more soluble in biological fluids than currently marketed chromium picolinate and can be well absorbed by the body. Third, our studies show that the new complex exhibits better in-vitro insulin enhancing activity than chromium picolinate.

Chromium picolinate is a popular nutritional supplement that has annual sales of several million dollars, so a new non-toxic alternative has great economic potential. The newly synthesized complex may prove to be a safer, more effective, and inexpensive class of drugs for preventative and therapeutic interventions in diabetes, insulin resistance, and related cardiovascular diseases.

If you would like to learn more about these novel patent-pending treatments and how your company may apply them in commercial situations, please contact the director of the University of Wyoming Research Products Center, Davona Douglass. We would be pleased to share further details.